KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Cash & Equivalents (2018 - 2022)

BioNTech SE's Cash & Equivalents history spans 6 years, with the latest figure at $12.5 billion for Q4 2023.

  • For Q4 2023, Cash & Equivalents fell 11.35% year-over-year to $12.5 billion; the TTM value through Dec 2023 reached $12.5 billion, down 11.35%, while the annual FY2023 figure was $12.6 billion, 13.72% down from the prior year.
  • Cash & Equivalents for Q4 2023 was $12.5 billion at BioNTech SE, down from $14.2 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $14.2 billion in Q4 2022 and bottomed at $574.6 million in Q4 2019.
  • The 5-year median for Cash & Equivalents is $1.9 billion (2021), against an average of $6.1 billion.
  • The largest annual shift saw Cash & Equivalents skyrocketed 631.05% in 2022 before it dropped 11.35% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $574.6 million in 2019, then skyrocketed by 151.12% to $1.4 billion in 2020, then surged by 34.2% to $1.9 billion in 2021, then skyrocketed by 631.05% to $14.2 billion in 2022, then decreased by 11.35% to $12.5 billion in 2023.
  • Per Business Quant, the three most recent readings for BNTX's Cash & Equivalents are $12.5 billion (Q4 2023), $14.2 billion (Q4 2022), and $1.9 billion (Q4 2021).